Shunxi Holding Group

China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm Cartherics Pty Ltd, securing the exclusive rights to develop, manufacture, and commercialize Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumors, including ovarian cancer, in Greater China. The agreement also grants…